CA2891556A1 - Use of il-1 beta binding antibodies for treating peripheral arterial disease - Google Patents

Use of il-1 beta binding antibodies for treating peripheral arterial disease Download PDF

Info

Publication number
CA2891556A1
CA2891556A1 CA2891556A CA2891556A CA2891556A1 CA 2891556 A1 CA2891556 A1 CA 2891556A1 CA 2891556 A CA2891556 A CA 2891556A CA 2891556 A CA2891556 A CA 2891556A CA 2891556 A1 CA2891556 A1 CA 2891556A1
Authority
CA
Canada
Prior art keywords
beta
binding antibody
seq
functional fragment
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2891556A
Other languages
English (en)
French (fr)
Inventor
Mark Fishman
Tom Thuren
Shi Yin Foo
Craig BASSON
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CA2891556A1 publication Critical patent/CA2891556A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
CA2891556A 2012-11-16 2013-11-14 Use of il-1 beta binding antibodies for treating peripheral arterial disease Abandoned CA2891556A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261727334P 2012-11-16 2012-11-16
US61/727,334 2012-11-16
PCT/US2013/070042 WO2014078502A1 (en) 2012-11-16 2013-11-14 Use of il-1 beta binding antibodies for treating peripheral arterial disease

Publications (1)

Publication Number Publication Date
CA2891556A1 true CA2891556A1 (en) 2014-05-22

Family

ID=49679654

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2891556A Abandoned CA2891556A1 (en) 2012-11-16 2013-11-14 Use of il-1 beta binding antibodies for treating peripheral arterial disease

Country Status (6)

Country Link
US (4) US10000565B2 (enExample)
EP (1) EP2919811B1 (enExample)
JP (1) JP2016502526A (enExample)
AU (1) AU2013344796B2 (enExample)
CA (1) CA2891556A1 (enExample)
WO (1) WO2014078502A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180291097A1 (en) * 2015-06-04 2018-10-11 Craig Basson Use of il-1 beta binding antibodies to treat peripheral arterial disease
CA2988055A1 (en) 2015-06-04 2016-12-08 Novartis Ag Use of il-1 beta binding antibodies to treat peripheral arterial disease
CA2994043A1 (en) 2015-07-31 2017-02-09 Glaxosmithkline Intellectual Property Development Limited Antibody variants
JP7189017B2 (ja) * 2015-11-24 2022-12-13 コモンウェルス サイエンティフィック アンド インダストリアル リサーチ オーガナイゼーション 細胞培養におけるウイルスの生産
KR20190032436A (ko) * 2016-07-21 2019-03-27 노파르티스 아게 폐 유육종증의 증상을 치료하거나 완화하기 위한 il-1beta 결합 항체 카나키누맙의 용도
EP3551034A1 (en) 2016-12-07 2019-10-16 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
US20200315540A1 (en) 2016-12-14 2020-10-08 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an il-1 inhibitor
US20200207848A1 (en) * 2017-09-13 2020-07-02 Novartis Ag Use of il-1b binding antibodies for the treatment of alcoholic hepatitis
FI3852617T3 (fi) * 2018-09-20 2025-10-21 Sfj Pharma X Inc Vasta-ainefragmenttien käyttö tikagrelorin aktiivisuuden kääntämiseen
WO2020106757A1 (en) 2018-11-19 2020-05-28 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
CN121197633A (zh) 2019-12-13 2025-12-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
CN112402359A (zh) * 2020-11-04 2021-02-26 深圳前海鹰岗生物科技有限公司 一种抑制细胞炎症因子治疗痛风急性发作的聚合物微针及制备方法
US20260015427A1 (en) 2024-06-25 2026-01-15 Kiniksa Pharmaceuticals, Gmbh Formulations of anti-interleukin 1 receptor 1 antibodies

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0020685D0 (en) 2000-08-22 2000-10-11 Novartis Ag Organic compounds
EP3124045A3 (en) 2006-12-20 2017-05-03 Xoma (Us) Llc Treatment of il-1 beta related diseases
CA2722620A1 (en) 2008-03-26 2009-10-01 Orthologic Corp. Method of treating peripheral arterial disease
EP3002299A1 (en) 2008-06-03 2016-04-06 AbbVie Inc. Dual variable domain immunoglobulins and uses thereof
PE20100054A1 (es) * 2008-06-03 2010-03-03 Abbott Lab Inmunoglobulina con dominio variable dual
CA2735939A1 (en) * 2008-09-05 2010-03-11 Xoma Technology Ltd. Methods for improvement of beta cell function
EP2196476A1 (en) * 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
CN102369217A (zh) * 2009-01-29 2012-03-07 雅培制药有限公司 Il-1结合蛋白
BRPI1011228A2 (pt) 2009-05-29 2019-09-24 Xoma Technology Ltd. métodos para reduzir um evento cardiovascular em um indivíduo, mortalidade seguindo um evento cardiovascular em um indivíduo e restenose em um indivíduo seguindo um procedimento de revascularização, e, para tratar um evento cardiovascular em um indivíduo e hipertensão aguda em um indivíduo.
TW201124427A (en) * 2009-10-15 2011-07-16 Abbott Lab IL-1 binding proteins
US8735546B2 (en) * 2010-08-03 2014-05-27 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
WO2013049278A1 (en) * 2011-09-30 2013-04-04 Novartis Ag USE OF IL-1 ß BINDING ANTIBODIES

Also Published As

Publication number Publication date
AU2013344796A1 (en) 2015-05-07
US20210317202A1 (en) 2021-10-14
US20200148759A1 (en) 2020-05-14
AU2013344796B2 (en) 2016-11-10
US10000565B2 (en) 2018-06-19
EP2919811B1 (en) 2018-12-26
US20180258166A1 (en) 2018-09-13
JP2016502526A (ja) 2016-01-28
EP2919811A1 (en) 2015-09-23
US20160326243A1 (en) 2016-11-10
WO2014078502A1 (en) 2014-05-22

Similar Documents

Publication Publication Date Title
AU2013344796B2 (en) Use of IL-1 beta binding antibodies for treating peripheral arterial disease
US20230293683A1 (en) Methods of treating ankylosing spondylitis using il-17 antagonists
CA2849466C (en) Use of il-1.beta. binding antibodies
US20230265182A1 (en) Use of il-1 beta binding antibodies to treat peripheral arterial disease
JP2017510627A (ja) 多発性硬化症の併用治療
US20230331834A1 (en) Method of treating tendinopathy using interleukin-17 (il-17)
WO2015083120A1 (en) USE OF IL-1β BINDING ANTIBODIES
JP2025516723A (ja) インターロイキン－１７（ｉｌ－１７）アンタゴニストを使用して腱障害を選択的に治療する方法
US20180291097A1 (en) Use of il-1 beta binding antibodies to treat peripheral arterial disease
RU2806304C1 (ru) Фармацевтическая композиция для профилактики и/или лечения атопического дерматита, включающая антагонист ил-31 в качестве активного ингредиента

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20181113

FZDE Discontinued

Effective date: 20210831